FDA takes steps to encourage more informative labeling on prescription drug and biological products' indications and usage

FDAToday, the U.S. Food and Drug Administration issued a draft guidance to provide recommendations for consideration when drafting the Indications and Usage section of human drug and biological product labeling. The FDA regulations require the Indications and Usage section of drug labeling to state that the drug is indicated for the treatment, prevention, mitigation, cure or diagnosis of a disease or condition, or for the relief of the disease or condition’s symptoms.

"FDA-approved labeling is the primary communication tool for providing information on the safe and effective use of drugs to the medical community," said Jacqueline Corrigan-Curay, M.D., J.D., director of the Office of Medical Policy in FDA's Center for Drug Evaluation and Research. "This guidance provides recommendations for drafting the Indications and Usage section of the labeling, including a discussion of the scope of an indication and the inclusion of age groups in indications. We believe this guidance will help health care providers identify appropriate treatment options for their patients."

The draft guidance, "Indications and Usage Section of Labeling for Human Prescription and Biological Products - Content and Format," describes the FDA’s recommendations for how to clearly convey such information and addresses circumstances where FDA regulations require that other information, in addition to the identification of the disease or condition, be included in the Indications and Usage section. As explained in the draft guidance, the Indications and Usage section should make clear the scope of the indication. The draft guidance describes circumstances in which an indication that is either broader or narrower than the parameters of the clinical studies supporting approval may be appropriate. The draft guidance also recommends the inclusion of age groups in the indication.

This guidance is one in a series of guidances the agency is developing or has developed to assist applicants with the content and format of labeling for human prescription drug and biological products. The labeling requirements and these guidances are intended to make information in the labeling easier for health care providers and patients to access, read and use.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Most Popular Now

How SARS-CoV-2 mutates to escape antibody binding

In a recurring pattern of evolution, SARS-CoV-2 evades immune responses by selectively deleting small bits of its genetic sequence, according to new research from the Uni...

Early functional SARS-COV-2 specific T cell respon…

Humoral and cellular adaptive immunity are two immune mechanisms that act against pathogens. Humoral immunity is mediated by antibodies, while cellular immunity does not ...

Anticancer drug may improve outcome for severe COV…

Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China ...

One dose of COVID-19 vaccine provokes strong immun…

Although clinical trial data are encouraging, real-world evidence with regard to the COVID-19 vaccine remains scarce. In particular, response to the vaccine among those p...

Johnson & Johnson announces submission of appl…

Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen Biotech, Inc., has submitted an application to the U.S. Food and Drug Administration (FDA) requesting E...

CureVac initiates rolling submission with European…

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today annou...

Pfizer and BioNTech publish data from in vitro stu…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the publication in Nature Medicine of data from in vitro studies that demonstrate that sera from in...

COVID-19 Vaccine AstraZeneca recommended for use i…

AstraZeneca's COVID-19 vaccine has been recommended for conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 c...

Roche announces the upcoming launch of the SARS-Co…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced it has obtained the CE mark for its new SARS-CoV-2 Rapid Antigen Test Nasal. The test will be available in countries acceptin...

Sinovac receives conditional marketing authorizati…

Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced that the China National Medical Produ...

A machine-learning approach to finding treatment o…

When the COVID-19 pandemic struck in early 2020, doctors and researchers rushed to find effective treatments. There was little time to spare. "Making new drugs takes fore...

Bayer to manufacture mRNA vaccine in Germany

In a joint press briefing today together with German Health Minister Jens Spahn, Minister-President of North Rhine-Westphalia, Armin Laschet, and Chief Executive Officer ...